SurModics Licenses Hydrophilic Coating for Elixir’s Drug-Eluting, Bare Metal Stents
October 31, 2008 - Surface modification and drug delivery technologies company SurModics Inc. said today it is providing advanced hydrophilic coating technology for Elixir Medical Corp’s drug-eluting and bare metal stent systems, which are designed to optimize vessel scaffolding and localized drug delivery to provide a safe and effective treatment for cardiovascular patients.
Elixir has conducted five first-in-human clinical studies evaluating the therapeutic effectiveness of the company’s Novolimus-eluting and Myolimus-eluting stent systems. Novolimus and Myolimus are macrocyclic lactones in the same family as Rapamycin. The macrocyclic lactone drugs represent the most widely utilized drug family for drug-eluting stent applications and have an established safety and efficacy profile.
For more information: www.surmodics.com, www.elixirmedical.com
More like this
- Elixir Announces Positive First-In-Man Results for Three DES With Durable, Bioabsorbable Polymers
- SurModics Inc.
- SurModics, Paragon Develop DES to Combat Late Stent Thrombosis
- Trial Begins for Novolimus-Eluting Stent With Bioabsorbable Polymer
- Expanded Agreement Gives St. Jude Medical Broader Use of SurModics' Cardiac Technologies